Intravenous injection of IL-2/HSP70-treated NK cells, which targeted GBM cells in the brain, did further confirm the effectiveness of activated NK cells, which exhibited specific homing properties, accumulating in the brain, and reaching the tumor cells. This evidence concerns the gene IL2 and glioblastoma.